Rachel Abudu

Rachel Abudu

Auto-generated profile, based on publicly available information

Rachel Abudu

Department of Health Services Research and Policy, Faculty of Public Health Policy, London School of Hygiene and Tropical Medicine , London WC1E 7HT

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2016 in Bioethics
Verified
Journal Article
Closed access
PDF file
SCShawneequa L. Callier
Shawneequa L. Callier
RARachel Abudu
Rachel Abudu
MMMaxwell J. Mehlman
Maxwell J. Mehlman
MSMendel E. Singer
Mendel E. Singer
DNDuncan Neuhauser
Duncan Neuhauser
GWGeorgia L. Wiesner
Georgia L. Wiesner

9 August 2022 in Health Research Policy and Systems
Verified
Journal Article
Open access
PDF file
RARachel Abudu
Rachel Abudu
KOKathryn Oliver
Kathryn Oliver
ABAnnette Boaz
Annette Boaz
As pressures to maximize research funding grow, biomedical research funders are increasingly tasked with demonstrating the long-term and real-world impacts of their funded research investments. Over the past three decades, research impact assessments (RIA) have emerged as an important tool for analysing the impacts of research by incorporating logic models, frameworks and indicators to track measures of knowledge production, capacity-building, development of research products, adoption of research into clinical guidelines and policies, and the realization of health, economic and social benefits. While there are currently several models for RIA within the literature, less attention has been paid to how funders can practically select and implement a RIA model to demonstrate the impacts of their own research portfolios. In this paper, a literature review was performed to understand (1) which research funders have performed RIAs of their research portfolios to date; (2) how funders have designed their assessments, including the models and tools they have used; (3) what challenges to and facilitators of success have funders found when adopting the RIA model to their own portfolio; and (4) who participates in the assessments. Forty-four papers from both published and grey literature were found to meet the review criteria and were examined in detail. There is a growing culture of RIA among funders, and included papers spanned a diverse set of funders from 10 countries or regions. Over half of funders (59.1%) used a framework to conduct their assessment, and a variety of methods for collecting impact data were reported. Issues of methodological rigour were observed across studies in the review, and this was related to numerous challenges funders faced in designing timely RIAs with quality impact data. Over a third of articles (36.4%) included input from stakeholders, yet only one article reported surveying patients and members of the public as part of the assessment. To advance RIA among funders, we offer several recommendations for increasing the methodological rigour of RIAs and suggestions for future research, and call for a careful reflection of the voices needed in an impact assessment to ensure that RIAs are having a meaningful impact on patients and the public.

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
RARachel Abudu
Rachel Abudu
GBGauthier Bouche
Gauthier Bouche
KBKarima Bourougaa
Karima Bourougaa
LDLynne Davies
Lynne Davies
KDKalina Duncan
Kalina Duncan
KWKari Wojtanik
Kari Wojtanik
The International Cancer Research Partnership (ICRP) is an active network of cancer research funding organizations, sharing information about funded research projects in a common database. Data are publicly available to enable the cancer research community to find potential collaborators and avoid duplication. This study presents an aggregated analysis of projects funded by 120 partner organizations and institutes in 2006-2018, to highlight trends in cancer research funding. Overall, the partners’ funding for cancer research increased from $5.562 billion (bn) US dollars (USD) in 2006 to $8.511bn USD in 2018, an above-inflation increase in funding. Analysis by the main research focus of projects using Common Scientific Outline categories showed that Treatment was the largest investment category in 2018, followed by Early Detection, Diagnosis, and Prognosis; Cancer Biology; Etiology; Control, Survivorship, and Outcomes; and Prevention. Over the 13 years covered by this analysis, research funding into Treatment and Early Detection, Diagnosis, and Prognosis had increased in terms of absolute investment and as a proportion of the portfolio. Research funding in Cancer Biology and Etiology declined as a percentage of the portfolio, and funding for Prevention and Control, Survivorship and Outcomes remained static. In terms of cancer site–specific research, funding for breast cancer and colorectal cancer had increased in absolute terms but declined as a percentage of the portfolio. By contrast, investment for brain cancer, lung cancer, leukemia, melanoma, and pancreatic cancer increased both in absolute terms and as a percentage of the portfolio.

22 July 2024 in Research Evaluation
Verified
Journal Article
Open access
RARachel Abudu
Rachel Abudu
KOKathryn Oliver
Kathryn Oliver
ABAnnette Boaz
Annette Boaz
The field of research impact assessment (RIA) has seen remarkable growth over the past three decades. Increasing numbers of RIA frameworks have been developed and applied by research funders and new technologies can capture some research impacts automatically. However, RIAs are too different to draw comparable conclusions about what type of methods, data or processes are best suited to assess research impacts of different kinds, or how funders should most efficiently implement RIAs. To usher in the next era of RIA and mature the field, future RIA methodologies should become more transparent, standardized and easily implementable. Key to these efforts is an improved understanding of how to practically implement and report on RIA at the funder-level. Our aim is to address this gap through two major contributions. First, we identify common items across existing best practice guidelines for RIA, creating a preliminary reporting checklist for standardized RIA reporting. Next, we systematically reviewed studies examining funders’ assessment of biomedical grant portfolios to examine how funders reported the results of their RIAs across the checklist, as well as the operational steps funders took to perform their RIA and the variation in how funders implemented the same RIA frameworks. We compare evidence on current RIA practices with the reporting checklist to identify good practice for RIA reporting, gaps in the evidence base for future research, and recommendations for future effective RIA.

1 June 2016 in Journal of Global Oncology
Verified
Journal Article
Open access
ACAli Chisti
Ali Chisti
NSNour Sharara
Nour Sharara
MGManaswi Gupta
Manaswi Gupta
JCJane Craycroft
Jane Craycroft
IRIlyana Rosenberg
Ilyana Rosenberg
FHFranklin Huang
Franklin Huang
39 Background: In response to the growing burden of cancer, Global Oncology, Inc., and the National Cancer Institute Center for Global Health launched a free, online, interactive map, the Global Cancer Project Map (GCPM) [ http://gcpm.globalonc.org ], to allow policy makers, researchers, and civil society around the world to search this central repository of international cancer control and research projects. The GCPM serves to catalyze collaboration in cancer research and clinical care, as well as inform research and care gaps. Methods: In addition to search options by project attributes, the GCPM provides map overlays of epidemiological measures using IARC’s GLOBOCAN cancer-specific estimates of incidence, prevalence, and mortality, cancer disability--adjusted life years, and UN Human Development Index country values. Currently, the map displays projects with international collaborators collated from the NCI, NCI-Designated Cancer Centers, UICC and ASCO. Results: The GCPM search options offer countless angles of looking at projects worldwide. Of the 1,479 currently-mapped projects, 44.8% have investigators or collaborators in less-developed countries (LDCs) (as defined by the UN). Of the 1218 with a project type classification, 104 relate to capacity building and/or training, with 69 of these projects (66.3%) occurring in LDCs. Utilizing the cancer type search options, the GCPM currently displays 54 cervical cancer projects with LDC collaborators, where the cervical cancer mortality age--standardized risk is more than 2.5 times higher for LDCs than more-developed countries. Conclusions: The GCPM is a real-time needs assessment tool to allow the cancer community to visualize international efforts in cancer control and link need to action. To better address the growing burden of cancer, the partnership is actively seeking collaboration and additional project submissions. Utilized with cancer statistic overlays, the GCPM can help develop regional priorities in cancer research and control. Funding: This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: Ali Chisti No relationship to disclose Nour Sharara No relationship to disclose Manaswi Gupta No relationship to disclose Jane Craycroft No relationship to disclose Ilyana Rosenberg Employment: Connance, Inc., Hayes Management Consulting Camille Morgan No relationship to disclose Kalina Duncan No relationship to disclose Rachel Abudu No relationship to disclose Billy Andre No relationship to disclose Shannon Silkenson No relationship to disclose Jennifer Silva No relationship to disclose Ami Bhatt No relationship to disclose Ted Trimble No relationship to disclose Franklin Huang Stock or Other Ownership: GlaxoSmithKline, Abbvie

1 October 2018 in Journal of Global Oncology
Verified
Journal Article
Closed access
MCM. Cira
M. Cira
RAR. Abudu
R. Abudu
DPD. Pyle
D. Pyle
SAS. Akhavan
S. Akhavan
KDK. Duncan
K. Duncan
Background: The US National Cancer Institute (NCI) Center for Global Health (CGH) serves as a clearinghouse of information on global oncology activities within the NCI and across the 70 NCI-designated Cancer Centers. Global oncology, as defined by the American Society of Clinical Oncology (ASCO), “addresses disparities and differences in cancer prevention, care, research, education and the disease's social and human impact around the world”. While CGH routinely reports on NCI-funded global oncology projects conducted at the cancer centers, there is limited reporting of non-NCI funded global oncology activities of the cancer centers. To address this gap, CGH has surveyed the cancer centers about their global oncology programs and projects informally in 2012 and 2014. The 2018 survey, in partnership with ASCO, represents the first systematically conducted survey, with new questions about cancer center global oncology programs, faculty, and trainees. Aim: The aim of the 2018 survey is to develop a summary report of cancer center global oncology programs for use by cancer centers as a knowledge sharing and collaborative tool; by the NCI to inform program development; and, by ASCO to better understand the current state of global oncology training at US institutions. Methods: CGH developed a 2-part online survey with questions about global oncology projects led by cancer centers, and the level of support for global oncology training and faculty engagement at cancer centers. CGH piloted the survey to 7 of the 70 cancer centers (10%) from January to March 2018. Revisions based on the pilot were made, and CGH fielded the survey to the rest of the 63 cancer centers (90%) from March to July 2018. CGH supplemented the survey data with an Internet search of cancer centers' Web sites. The submitted data will be compiled, analyzed, and organized into a summary report for distribution to NCI, ASCO, and the cancer centers. Results: Data from the 7 pilot institutions show that while all 7 institutions (100%) have a global oncology program, there is great variance in the percentage of global oncology faculty who receive external or administrative research grant support for their work. Three institutions (43%) report that 50% or fewer global oncology faculty receive external research grant support, and 6 institutions (86%) report that 50% or fewer global oncology faculty receive cancer center administrative fund support for their work. Additional results and analysis will be available and presented as part of this presentation. Conclusion: In addition to serving as a knowledge sharing and collaboration tool for cancer centers, the global oncology survey allows NCI, ASCO, and global oncology partners to understand the current landscape of and sources of support for global oncology training, research, and programming at the cancer centers. This information will inform future discussions on how to strengthen global oncology programming and partnerships.